Novacyy 20190526 Sd Upd Patched -

: During this window, Novacyt was in the process of selling non-core assets, such as its NOVAprep unit and clinical laboratory business, to focus on molecular testing.

In early 2019, Novacyt was in a transitional phase. The company was actively streamlining its operations to focus on its high-growth diagnostic products, particularly through its and Lab21 brands. novacyy 20190526 sd upd

: In May 2019, the company’s molecular division, Primerdesign , launched the genesig® q32 qPCR instrument. This next-generation tool was a critical "update" to their hardware lineup, designed to provide faster PCR cycle times. : During this window, Novacyt was in the

: Internal database records or software updates for their diagnostic instruments (like the genesig® series). : In May 2019, the company’s molecular division,

While "SD UPD" is often technical shorthand, in the context of Novacyt’s 2019 operations, it may refer to:

The period following May 2019 marked a radical shift for the company. By January 2020, Novacyt became a household name in the biotech sector by launching one of the first molecular tests for . Half Year Results | Novacyt

: Documentation regarding the hand-over or operational changes during the divestment of their clinical lab units.